Gynecologic malignancies, mainly including ovarian cancer, cervical cancer and endometrial cancer, are leading causes of death among women worldwide with high incidence and mortality rate. Recently, adoptive T cell therapy (ACT) using engineered T cells redirected by genes which encode for tumor-specific T cell receptors (TCRs) or chimeric antigen receptors (CARs) has demonstrated a delightful potency in B cell lymphoma treatment. Researches impelling ACT to be applied in treating solid tumors like gynecologic tumors are ongoing. This review summarizes the preclinical research and clinical application of engineered T cells therapy for gynecologic cancer in order to arouse new thoughts for remedies of this disease.
CITATION STYLE
Xu, Y., Jiang, J., Wang, Y., Wang, W., Li, H., Lai, W., … Wu, S. (2021, July 27). Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2021.725330
Mendeley helps you to discover research relevant for your work.